000303443 001__ 303443
000303443 005__ 20250817022053.0
000303443 0247_ $$2doi$$a10.1016/j.trecan.2025.07.005
000303443 0247_ $$2pmid$$apmid:40783365
000303443 0247_ $$2ISSN$$a2405-8033
000303443 0247_ $$2ISSN$$a2405-8025
000303443 0247_ $$2altmetric$$aaltmetric:180167133
000303443 037__ $$aDKFZ-2025-01656
000303443 041__ $$aEnglish
000303443 082__ $$a610
000303443 1001_ $$0P:(DE-He78)b5f03547ed92823fcfbfc70c5ec2712e$$aBraun, Lukas M$$b0$$udkfz
000303443 245__ $$aClinical perspective and treatment of immune-related colitis after cancer immunotherapy.
000303443 260__ $$aAmsterdam$$bElsevier$$c2025
000303443 3367_ $$2DRIVER$$aarticle
000303443 3367_ $$2DataCite$$aOutput Types/Journal article
000303443 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754913055_15678$$xReview Article
000303443 3367_ $$2BibTeX$$aARTICLE
000303443 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303443 3367_ $$00$$2EndNote$$aJournal Article
000303443 500__ $$aepub
000303443 520__ $$aTargeting negative regulators of immunity with immune-checkpoint inhibitors (ICIs) has led to significant survival benefit in patients with various cancer entities. ICI therapy disrupts mechanisms of immune tolerance, which induces inflammatory toxicities in different target organs, summarized as immune-related adverse events (irAEs) in some patients. ICI-colitis relies on the activation of intestinal tissue-resident memory T cells (TRM cells) and is one of the most frequently observed immune-related toxicities; it can be fatal if untreated. The disease is associated with highly cytotoxic intestinal T cells and inflammatory myeloid activation. Current clinical management relies on broad immunosuppression, potentially reducing antitumor immunity. Ideal future therapies for irAEs will uncouple immunosuppressive activities in the inflamed target organ and the tumor microenvironment.
000303443 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000303443 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303443 650_7 $$2Other$$aanticancer immunity
000303443 650_7 $$2Other$$acancer immunotherapy
000303443 650_7 $$2Other$$acheckpoint blockade
000303443 650_7 $$2Other$$acolitis
000303443 650_7 $$2Other$$aimmune-checkpoint inhibitor
000303443 650_7 $$2Other$$aimmune-related adverse events
000303443 650_7 $$2Other$$aimmune-related colitis
000303443 650_7 $$2Other$$ainflammatory toxicities
000303443 7001_ $$aLu, Yunjie$$b1
000303443 7001_ $$0P:(DE-HGF)0$$aZeiser, Robert$$b2
000303443 773__ $$0PERI:(DE-600)2852626-0$$a10.1016/j.trecan.2025.07.005$$gp. S2405803325001748$$pnn$$tTrends in cancer$$vnn$$x2405-8033$$y2025
000303443 909CO $$ooai:inrepo02.dkfz.de:303443$$pVDB
000303443 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b5f03547ed92823fcfbfc70c5ec2712e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000303443 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000303443 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000303443 9141_ $$y2025
000303443 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRENDS CANCER : 2022$$d2024-12-18
000303443 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bTRENDS CANCER : 2022$$d2024-12-18
000303443 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK Koordinierungsstelle Freiburg$$x0
000303443 980__ $$ajournal
000303443 980__ $$aVDB
000303443 980__ $$aI:(DE-He78)FR01-20160331
000303443 980__ $$aUNRESTRICTED